HomeHealthcare & Life SciencesPharmaceuticals Myasthenia Gravis Treatment Market

Middle East And Africa Myasthenia Gravis Treatment Market Size & Outlook, 2025-2033


Middle East And Africa Myasthenia Gravis Treatment Market Insights

  • Reed Intelligence analysis indicates that the Middle East And Africa Myasthenia Gravis Treatment Market size, which was USD 227.88 Million in 2024, is projected to attain USD 551.8 Million by 2033.
  • The market is expected to register a CAGR of 10.35% over the period 2026–2033.
  • In 2024, Ocular MG  emerged as the dominant By Type based on market size.
  • Congenital MG  is projected to register the fastest growth, positioning it as the most attractive By Type segment over the forecast horizon.

Other Key Findings


  • The global Myasthenia Gravis Treatment Market size saw Middle East And Africa holding a share of 10.8% in 2024.
  • United States is forecasted to account for the leading share of the global market by 2033.
  • In Middle East and Africa, United Arab Emirates is forecasted to be the fastest-expanding market, projected to reach USD 232.23 Million by 2033.

Report Summary

Report Scope Details
Base Year for Study 2024
Study Period 2021-2033
Historical Period 2021-2023
Forecast Period 2025-2033
Market Size In 2024 USD 227.88 Million
Market Size In 2033 USD 551.8 Million
Largest segment Ocular MG 
Units Revenue in USD Million
CAGR 10.35% (2025-2033)
Segmnetation Covered
Middle East and Africa
  1. United Arab Emirates
  2. Saudi Arabia
  3. South Africa
  4. Egypt
  5. Nigeria
  6. Turkey
By Type
  1. Ocular MG 
  2. Congenital MG 
  3. Transient Neonatal MG
By Treatment
  1. Medication 
  2. Surgery 
  3. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
  4. Plasmapheresis and Intravenous Immunoglobulin 
  5. Others
By End-User
  1. Hospitals 
  2. Clinics 
  3. Academic Research Institutes 
  4. Others
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Related Reports